NASDAQ:NMTC - Nasdaq - US64130M2098 - Common Stock - Currency: USD
0.6229
+0.01 (+1.12%)
The current stock price of NMTC is 0.6229 USD. In the past month the price decreased by -4.46%. In the past year, price decreased by -41.24%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.47 | 228.44B | ||
ISRG | INTUITIVE SURGICAL INC | 70.62 | 193.38B | ||
BSX | BOSTON SCIENTIFIC CORP | 38.7 | 154.60B | ||
SYK | STRYKER CORP | 30.06 | 143.93B | ||
MDT | MEDTRONIC PLC | 14.67 | 103.48B | ||
BDX | BECTON DICKINSON AND CO | 12.16 | 49.12B | ||
EW | EDWARDS LIFESCIENCES CORP | 28.84 | 44.09B | ||
IDXX | IDEXX LABORATORIES INC | 44 | 40.65B | ||
RMD | RESMED INC | 26.74 | 35.61B | ||
DXCM | DEXCOM INC | 51.22 | 33.14B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.03 | 31.66B | ||
STE | STERIS PLC | 26.02 | 23.87B |
NeuroOne Medical Technologies Corp. is a medical technology company, which engages in the development and commercialization of thin film electrode technology for continuous electroencephalogram and stereoelectrocencephalography recording, spinal cord stimulation, brain stimulation, and ablation solutions. The company is headquartered in Eden Prairie, Minnesota and currently employs 17 full-time employees. The company went IPO on 2012-11-09. The company is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. The company may also pursue applications for other areas such as depression, mood disorders, incontinence and artificial intelligence. Its products include Evo cortical electrode technology for recording, monitoring, and stimulating brain tissue for up to 30 days; Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain, and OneRF ablation system for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures.
NEUROONE MEDICAL TECHNOLOGIE
7599 Anagram Dr
Eden Prairie MINNESOTA US
Employees: 16
Phone: 19524261383
The current stock price of NMTC is 0.6229 USD. The price increased by 1.12% in the last trading session.
The exchange symbol of NEUROONE MEDICAL TECHNOLOGIE is NMTC and it is listed on the Nasdaq exchange.
NMTC stock is listed on the Nasdaq exchange.
6 analysts have analysed NMTC and the average price target is 1.48 USD. This implies a price increase of 137.44% is expected in the next year compared to the current price of 0.6229. Check the NEUROONE MEDICAL TECHNOLOGIE stock analysts ratings, price target forecast and up-and down grades for more detailed information.
NEUROONE MEDICAL TECHNOLOGIE (NMTC) has a market capitalization of 31.03M USD. This makes NMTC a Nano Cap stock.
NEUROONE MEDICAL TECHNOLOGIE (NMTC) currently has 16 employees.
NEUROONE MEDICAL TECHNOLOGIE (NMTC) has a support level at 0.62 and a resistance level at 0.67. Check the full technical report for a detailed analysis of NMTC support and resistance levels.
The Revenue of NEUROONE MEDICAL TECHNOLOGIE (NMTC) is expected to grow by 93.92% in the next year. Check the estimates tab for more information on the NMTC EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
NMTC does not pay a dividend.
NEUROONE MEDICAL TECHNOLOGIE (NMTC) will report earnings on 2025-08-12, after the market close.
NEUROONE MEDICAL TECHNOLOGIE (NMTC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.65).
The outstanding short interest for NEUROONE MEDICAL TECHNOLOGIE (NMTC) is 0.99% of its float. Check the ownership tab for more information on the NMTC short interest.
ChartMill assigns a fundamental rating of 3 / 10 to NMTC. NMTC may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months NMTC reported a non-GAAP Earnings per Share(EPS) of -0.65. The EPS decreased by -3.17% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -110.68% | ||
ROE | -244.88% | ||
Debt/Equity | 0.6 |
ChartMill assigns a Buy % Consensus number of 43% to NMTC. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 34.09% and a revenue growth 93.92% for NMTC